Summary
Edwards Lifesciences Corporation (EW) reported strong financial performance for the quarter and six months ending June 30, 2014. Net sales increased by 11.2% and 8.2% respectively, driven primarily by growth in Transcatheter Heart Valves, particularly in Europe with the launch of the Edwards SAPIEN 3 valve. A significant event was the settlement of patent litigation with Medtronic, Inc., which resulted in a one-time upfront payment of $750.0 million to Edwards Lifesciences, substantially boosting net income for the period. Despite this one-time gain, the company's core operations demonstrated healthy sales expansion across its key product segments: Transcatheter Heart Valves, Surgical Heart Valve Therapy, and Critical Care.
Financial Highlights
46 data pointsBeta
Financial Statements
Beta
| Revenue | $575.10M |
| Cost of Revenue | $151.20M |
| Gross Profit | $423.90M |
| R&D Expenses | $89.10M |
| SG&A Expenses | $215.50M |
| Net Income | $547.00M |
| EPS (Basic) | $0.86 |
| EPS (Diluted) | $0.85 |
| Shares Outstanding (Basic) | 633.60M |
| Shares Outstanding (Diluted) | 644.40M |
Key Highlights
- 1Total net sales increased by 11.2% to $575.1 million for the three months ended June 30, 2014, and by 8.2% to $1,097.5 million for the six months ended June 30, 2014.
- 2Transcatheter Heart Valves sales showed robust growth of 20.6% and 16.2% for the three and six months, respectively, fueled by the SAPIEN 3 launch in Europe and SAPIEN XT launch in Japan.
- 3A significant one-time litigation settlement with Medtronic, Inc. resulted in an upfront payment of $750.0 million, substantially increasing net income to $547.0 million for the quarter and $607.3 million for the six months.
- 4Gross profit margin decreased slightly to 73.7% for the quarter and 72.9% for the six months, attributed to foreign currency impacts and a sales reserve for transcatheter heart valve product returns related to new product introductions.
- 5Selling, General, and Administrative (SG&A) expenses increased, primarily due to higher sales and marketing expenses to support the Transcatheter Heart Valve program and a larger incentive compensation accrual.
- 6Research and Development expenses remained robust, representing 15.5% and 15.9% of net sales for the respective periods, indicating continued investment in innovation.
- 7The company announced a new Five-Year Credit Agreement providing up to $750.0 million in borrowings, replacing the previous facility, and continued its share repurchase program.
Frequently Asked Questions
The substantial increase in net income was primarily driven by a one-time $750.0 million upfront payment received from Medtronic, Inc. as part of a settlement agreement resolving all outstanding patent litigation between the two companies.
Transcatheter Heart Valve sales experienced strong growth, with a 20.6% increase for the quarter and 16.2% for the six months. This growth was primarily attributed to the successful launch of the Edwards SAPIEN 3 valve in Europe and the ongoing launch of the Edwards SAPIEN XT valve in Japan. However, sales in the U.S. were impacted by customer conversion to consignment and a reserve for estimated product returns related to upcoming next-generation valve introductions.
Beyond boosting net income, the $750.0 million settlement payment was recognized within 'Intellectual Property Litigation (Income) Expense, net' on the Statement of Operations. A portion of the consideration was allocated to future royalties and license agreements, which will be recognized in Net Sales over the term of the license, rather than recognized upfront.
Yes, Selling, General, and Administrative (SG&A) expenses increased due to higher sales and marketing efforts for the Transcatheter Heart Valve program and increased incentive compensation accruals. Research and Development expenses also saw an increase, reflecting continued investment in clinical studies and new product development, maintaining a consistent percentage of net sales.